BICO Group AB
Research BICO Group AB (BICO) on Bullrun: market cap SEK 1.40B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBICO
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryMedical Devices
- CurrencySEK
- Market capSEK 1.40B
- Financial periodQ1 2026
- RevenueSEK 329.90M
- Net income-SEK 131.30M
- Free cash flowSEK 42.30M
- Gross margin54.1%
Valuation Snapshot
latest market cap is SEK 1.40B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 1.50B | -SEK 1.09B | n/a | 52.1% | n/a | SEK 1.20B | SEK 1.29B | SEK 1.75B |
| FY2024 | SEK 1.95B | -SEK 9.00M | SEK 114.30M | 51.8% | -8 | SEK 946.30M | SEK 1.34B | SEK 2.99B |
| FY2023 | SEK 2.01B | -SEK 1.17B | SEK 7.00M | 49.4% | -1662 | SEK 861.00M | SEK 1.42B | SEK 3.07B |
| FY2022 | SEK 2.12B | -SEK 835.70M | -SEK 543.50M | 105.2% | -1294 | SEK 925.20M | SEK 1.38B | SEK 4.27B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | SEK 1.40B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About BICO Group AB
BICO Group AB (publ) provides hardware, laboratory automation, and software solutions in North America, Europe, Asia, and internationally. It operates through two segments: Life Science Solutions and Lab Automation. The Bioprinting segment offers 3D bioprinters and bioinks with a range of technologies for various applications, resolutions, and volume/speed requirements, as well as provides services focused on accelerating drug discovery and development.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BICO Group AB's market cap?
BICO Group AB's market capitalization is SEK 1.40B.
What does BICO Group AB do?
BICO Group AB (publ) provides hardware, laboratory automation, and software solutions in North America, Europe, Asia, and internationally. It operates through two segments: Life Science Solutions and Lab Automation. The Bioprinting segment offers 3D bioprinters and bioinks with a range of technologies for various applications, resolutions, and volume/speed requirements, as well as provides services focused on accelerating drug discovery and development.